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Since ALK targeting TKIs (ALK-TKIs) typically fail to eradicate all of the tumor cells, the 68 survivors can evolve resistance-conferring phenotypic adaptations, culminating in the outgrowth 69 of resistant subpopulations and eventual clinical relapse. Though we know that tumors change 70
and evolve under drug-imposed selective pressures, this knowledge is not accounted for in the 71 standard of care in clinical practice, where tumors are treated as static entities, with therapy 72 switched only after relapse. Adequate understanding of the evolutionary trajectories and 73 underlying dynamics might offer an opportunity to drastically improve clinical outcomes with 74 therapeutic tools that are already at our disposal [2] [3] [4] [5] . For example, by accounting for frequency 75 dependent selection and fitness tradeoffs a pilot clinical trial in castration resistant prostate 76 cancer significantly extended progression free survival while reducing side effects of the 77 treatment, using different scheduling of standard therapy drugs 6 . 78 79
In contrast to massive research efforts that have advanced our understanding of the molecular 80 mechanisms of resistance, evolutionary dynamics during the acquisition of resistance remains 81 understudied. Consequently, our conceptual understanding of how resistance evolves, which 82 inform mathematical modeling studies, is often based on conjectures from mechanistic studies, 83 rather than direct experimental inquiry suitable for informing quantitative models. For example, 84 demonstrations of the pre-existence of therapy-associated molecular alterations in sub-85 populations of tumor cells within treatment naïve samples have led to the widely prevalent 86 assumption that resistance to targeted therapies arises simply due to a competitive release of 87 pre-existent genetically (or epigenetically) distinct, therapy-resistant subpopulations under drug-88 imposed selective pressures 7, 8 . On the other hand, a growing body of experimental studies 89 suggest that therapy resistance can emerge de novo from drug-tolerant persister (DTP) cells 9 , 90 capable of surviving in the drugs and limited proliferation, but incapable of supporting robust 91 tumor growth. DTPs are often assumed to constitute a phenotypically well-defined sub-92 population, and sometimes equated with cancer stem cells 10 . While DTP cells cannot sustain 93 positive net tumor growth in the face of therapy, they can maintain residual disease and serve 94 as a substrate for mutational or epigenetic conversions to therapy-resistant phenotypes, 95 capable of driving robust growth rates in the face of therapy 9 . Finally, as therapies can induce 96 adaptive phenotypic changes on shorter time scales, independent of selection for more fit 97 phenotypes, development of resistance has also been viewed from a 98 differentiation/reprograming paradigm [11] [12] [13] . 99 100
Motivated by our interest in developing evolutionary informed therapeutic scheduling to tackle 101 TKI resistance, we decided to investigate the origin and evolutionary dynamics that underlie the 102 rapid development of therapy resistance of an in vitro model of ALK+ NSCLC, the patient 103 derived H3122 cell line. We found that, upon exposure to different ALK-TKIs, NCI-H3122 cells 104 rapidly and predictably develop strong drug resistance. Resistance originates de novo, from 105 weakly resistant heterogeneous sub-populations, which differ in fitness when exposed to 106 different ALK-TKIs. Levels of resistance gradually increase under therapy, through acquisition of 107 multiple cooperating genetic and epigenetic mechanisms, through TKI-specific phenotypic 108 trajectories. In contrast to therapy naïve or fully resistant cells, these evolving populations show 109 strong collateral sensitivity to the dual EGFR/HER2 inhibitor lapatinib, suggesting a temporally 110 restricted opportunity to interfere with the development of resistance. 111 112 RESULTS. 113 114 I. Continuous exposure to ALK-TKIs leads to acquired resistance mediated by 115 predictably distinct phenotypes. 116 To understand the development of acquired resistance to ALK-TKIs, we took advantage of a 117 well-characterized ALK+ NSCLC cell line, NCI-H3122, which can rapidly develop resistance to 118 multiple clinically relevant ALK-TKIs using dose escalation protocols 14 . Using resistant cell lines 119 from our previous study 14 , we continued dose escalation, eventually selecting for cells capable 120 of growing in high, clinically relevant concentrations of the drugs (up to 1 µM crizotinib, 4 µM 121 lorlatinib, 2 µM alectinib, 200 nM ceritinib). H3122 cells with evolved resistance to ALK-TKI 122 (erALK-TKI) displayed strong collateral resistance toward all other tested ALK-TKIs, with 5-100x 123 higher IC50 ( Fig. 1A and Table S1 ). Despite the similar shift in IC50 in all of the tested ALK-124
TKIs, erALK-TKI cells developed through selection by different inhibitors displayed more 125 divergent sensitivities to higher drug concentrations. Consistent with the clinical efficacy of 126 alectinib and lorlatinib as a second line therapy after failure of crizotinib 15, 16 , high concentrations 127 of alectinib and lorlatinib strongly inhibited cells with evolved resistance to crizotinib (erCriz) and 128 ceritinib (erCer). The resistance was at least partially heritable, as the erALK-TKI phenotypes 129
were partially or completely maintained after drug holiday (Fig. S1A) . Further, upon xenograft 130 transplantation into immunocompromised NSG mice, cells with evolved resistance to alectinib 131 (erAlec) and lorlatinib (erLor), formed tumors capable of maintaining net growth when 132 challenged with clinically relevant concentrations of alectinib and lorlatinib, despite the 3 week 133 gap between tumor implantation and initiation of the treatment (Fig. 1B, C) . 134 135
Whereas drug dose escalation protocols are commonly used in studies to identify resistance 136 mechanisms 17 , they do not reflect the development of resistance in clinics, as patients are 137 treated upfront with the highest tolerated dose of the drugs. Therefore, we asked whether 138 resistance can develop in the face of acute exposure to clinically relevant concentrations of 139 ALK-TKIs. To this end, we plated treatment naïve H3122 cells in the presence of 0.5 µM 140 crizotinib, 2 µM alectinib and lorlatinib or 100 nM ceritinib, replating cultures as needed to 141 relieve contact growth inhibition of the surviving cells. After 3-4 months of this selection, we 142 obtained rapidly proliferating erALK-TKI cell lines, with resistance levels comparable to those 143 achieved with the dose escalation protocol (Fig. 1D) . 144 145 We next asked to what extent the differences in cross-sensitivities of erALK-TKI cells towards 146 different ALK inhibitors are attributable to the choice of specific ALK inhibitor. To answer this, we 147 independently derived triplicate lines for each of the ALK-TKIs used in this study, with the acute 148 exposure protocol, and compared their cross-sensitivities to higher concentrations of the 149 inhibitors. Consistent with previous findings (Fig. 1A) , erLor and erAlec cells demonstrated 150 stronger resistance to high concentrations of different ALK-TKIs, compared to erCriz and erCer 151 cell lines (Fig. 1E) . Similar to the resistant cell lines derived by gradual exposure, resistant 152 phenotypes in cell lines derived by acute exposure to ALK-TKIs were largely heritable ( Fig.  153 S1B). 154 155
Given the surprising predictability in ALK-TKI cross-sensitivity phenotypes, we interrogated the 156 extent of predictability of changes in EML4-ALK dependent signaling pathways. Immunoblot 157 analyses, performed on cells cultured in the absence of the drugs for 48 hrs (to reduce the 158 direct impact of ALK-TKIs on cell signaling) revealed that all of the erCriz cell lines displayed 159 increased phosphorylation of EML4-ALK, in most cases in association with elevated EML4-ALK 160 protein levels, as well as increased STAT3 phosphorylation (Fig. 1F) . In contrast, all of the erLor 161 cell lines lacked the increase in STAT3 phosphorylation and displayed reduced ALK 162 phosphorylation. Instead, they expressed higher levels of EGFR, HER2, or both. erAlec and 163 erCer cell lines exhibited more diverse (less predictable) phenotypes. To assess the phenotypes 164 more globally, we examined mRNA expression levels of 230 cancer-related genes using 165 Nanostring nCounter GX human cancer reference panel. Principal component and hierarchical 166
clustering analyses for mRNA expression were largely consistent with the immunoblot 167 evaluation of phosphorylation (Fig. S2A, B) . erCer, evolved through acute selection, as well as 168 acutely and gradually evolved erCriz and erLor cells formed distinct clusters; in contrast, 169 phenotypes of erAlec were more diverse. 170 171
Potentially, observed differences could reflect either cell population-wide phenotypic changes or 172 differences in relative abundance of distinct pre-existent subpopulations. To discriminate 173 between these two possibilities, we performed single cell RNA sequencing of erALK-TKI cell 174 lines, focusing on two cell lines per specific ALK-TKI, with the highest divergence in PCA 175 analysis of NanoString data (Fig. S2A) . Uniform manifold approximation and projection 176 (UMAP)  18 dimension reduction of single cell expression data revealed relative phenotypic  177  homogeneity within individual ALK-TKI lines, with a high degree of similarity among cell lines  178 derived with the same inhibitor (Fig. 1G) . We transduced H3122 with a high complexity lentiviral ClonTracer library at a 214 low multiplicity of infection (MOI) to ensure that most of the transduced cells are labelled with a 215 single unique barcode. Following the elimination of non-transduced cells with puromycin 216 selection, and ~100x expansion of the barcoded cells, we took a baseline aliquot, then 217 separated the cells into parallel quadruplicate cultures, and exposed them to 0.5 µM alectinib, 218 lorlatinib, and crizotinib or DMSO control. After 4 weeks of incubation, barcode frequencies were 219 determined by next generation sequencing, and compared to the baseline frequencies (Fig.  220 2E) . Clear evidence of both negative and positive selection was observed in all treatment 221 groups (including DMSO controls), as barcode diversity, captured with Shannon diversity index, 222 decreased ( Fig. S3A) , while several subpopulations have expanded (Fig. S3B) . Spearman 223 ranking of barcodes, which increased in frequency above the highest barcode frequency 224 observed in the baseline sample, indicated a strikingly high degree of correlation between 225 biological replicates within the same treatment condition, indicating pre-existence of relatively 226 stable weakly resistant subpopulations (Fig. 2F) . However, correlation between samples treated 227 with different ALK TKIs was either absent or much less pronounced, indicating that selective 228 pressures exerted by different ALK TKIs might amplify distinct pre-existing weakly resistant sub-229 populations. Unsupervised hierarchical clustering analysis revealed a partial overlap between 230
"winning" clones (barcodes) across multiple ALK TKIs, indicating that at least some of the 231 distinctions reflect quantitative rather than qualitative differences, and some of the pre-existent 232 phenotypes were equally adaptable to different ALK TKIs (Fig. 2G) Having established that resistance originates from heterogeneous pre-existing tolerant 243 populations, we next asked how it progresses toward full resistance. The prevalent assumption 244 in the modeling, experimental and clinical communities is that resistance results from a single-245 hit, transition mediated by acquisition of a genetic mutation or by a (meta) stable change in 246 expression of resistance-conferring genes through a stochastic or drug-induced epigenetic 247 switch 7, 26 . To test whether resistance in H3122 cells develops through a single hit transition, we 248 employed the following clonogenic assay (Fig. 3A) . Therapy naïve cells were pre-cultured in the 249 presence of ALK-TKIs (crizotinib or lorlatinib) for 1-3 weeks, then harvested and seeded at 250 clonogenic densities in the presence or absence of the drug. After 7 days of culture, we 251 measured clonogenic survival as well as the sizes of the resulting colonies. Since prolonged 252 exposure to the drugs is expected to eliminate sensitive populations, while enriching for drug 253 tolerant and resistant ones, we expected the clonogenic proportion to increase over time. 254
Indeed, the clonogenic proportion in 0.5 µM crizotinib progressively increased from the initial 255 2.6% to 26% at week three, while the clonogenic proportion in 0.5 µM lorlatinib increased from 256 the initial 1% to 17% at week three (Fig. 3B) . Consistent with the lack of proliferation penalty in 257 the barcoding experiments, we did not observe substantial changes in size of colonies, formed 258 by cells with evolved or evolving resistance, in the absence of the drugs (Fig S4A, B) . If the 259 transition from tolerance to resistance were to result from a single-hit mutational or epigenetic 260 switch, we would expect to observe a bimodal distribution of colony sizes, representing tolerant 261 and resistant colonies, with the fraction of the latter gradually increasing (Fig. 3A) . As expected, 262 longer ALK TKI exposure lead to an increase in the average colony size. However, instead of 263 the expected bimodal size distribution, this increase was apparently homogeneous, suggesting 264 a gradual development of resistance (Fig. 3C) parameters: a) (epi) mutational probability and b) the number of mutational steps required to 293 reach maximum division probability (n). Since we do not know the (epi) mutation probability, we 294 explored the outcomes with the full range of possible values (0-1), and the number of mutational 295 steps ranging from 1 to 300. With each choice of parameters, we generated 100,000 random in 296 silico simulations (Fig. 3F and Suppl. video 2). Differences between in vitro and in silico colony 297 size distributions were assessed using Kullback-Leibler divergence. We found that a single 298 mutational step provided the poorest fit to the data for all mutation probabilities. The best fit was 299 achieved with a number of mutational steps in the range of 3-100 (Fig. 3G, H) . Notably, 300 inclusion of death rates, bi-directional change in cell fitness and consideration of mutations that 301 combine multiple increments at a single cell division did not qualitatively change this outcome 302 ( Fig. S4 E, F (Fig. 4C) . Parental cells formed few small colonies, 344 resembling tolerant colonies formed upon exposure to an ALK-TKI (Fig. 1D) . In contrast, erLor 345 cells formed multiple colonies that displayed no evidence of growth inhibition ( Fig. 4C) , despite 346 complete ablation of the protein expression of EML4-ALK gene (Fig. 4D) erALK-TKI cells (Fig. 4E) . Further, after exposure to crizotinib, cells with retrovirally 360 overexpressed EML4-ALK retained residual levels of ALK phosphorylation similar to those 361 observed in the erALK-TKI cells (Fig. S6A) . Despite this, EML4-ALK overexpressing cells 362 displayed only a marginal increase in crizotinib resistance (Fig. 4F) , suggesting that while ALK 363 amplification contributes to resistance, it is insufficient to fully account for it. 364 365
Given the insufficiency of EML4-ALK overexpression to fully account for resistance, we decided 366 to interrogate the functional impact of the most common resistance-associated point mutation, 367 L1196M, which is thought to provide a single hit resistance mechanism to crizotinib 29 . 368 Surprisingly, at low expression levels, achieved with <1 retroviral MOI, L1196M expression only 369 moderately decreased crizotinib sensitivity (Fig. 4G) . In contrast, higher overexpression of the 370 mutant protein, at levels similar to those observed with cells containing amplified "wild type" 371 fusion gene, achieved with high MOI, blocked the ability of crizotinib to shut down 372 phosphorylation of EML4-ALK, as well as its main downstream effector ERK (Fig. 4E, S6A , B), 373 and provided a resistance level that is similar or higher to that observed in erCriz cells (Fig. 4F) .
374
Whereas the results with L1196M overexpression are consistent with previously reported 375 sufficiency to confer resistance in NIH-H3122 cells 30, 31 , and ALK mutations do co-occur with 376 EML4-ALK amplification 32 , we are not aware of reports of amplification of ALK mutant alleles. 377
Thus, common resistance-associated mutational changes might be insufficient to provide a 378 single hit solution to the challenge posed by ALK-TKI induced selective pressures. 379 380
Next, we examined resistant cell lines for the presence of additional copy number alterations. 381
Whereas Oncomine Focus Assay 33 failed to detect additional common mutations, CytoScanHD 382 SNP array revealed additional genetic changes, including recurrent chromosomal amplifications 383 in chromosomes 2, 3, 12 and 17. Interestingly, 2 out of 3 examined erLor lines contained Chr12 384 p12.1-p11.1 amplification, containing KRAS, whereas a third one contained Chr1 p13.2-p12 385 amplification containing NRAS (Fig. S7A) . Notably, chromosomal amplification of genomic 386 regions containing KRAS and NRAS were associated with elevated expression of these proto-387 oncogenes (Fig. S7B) . 388 389
Given the growing evidence for the importance of recurrent (semi)heritable non-genetic changes 390 in gene expression in resistance to targeted and cytotoxic therapies, we used RNA-Seq analysis 391 to examine changes in gene expression after a 48 hr drug holiday (to reduce the direct impact of 392 ALK TKI on gene expression). We found multiple gene expression changes, previously 393 implicated in TKI and chemotherapy resistance, including increased expression of multiple 394
RTKs (EGFR, HER2, FGFR, AXL, EPHA2, etc.), cytokines, ECM & ECM receptors and other 395 types of molecules, suggesting a complex, multifactorial nature of resistance (Fig. 5A) . 396 Importantly, co-expression analysis of cell lines in the CCLE database revealed that the genes 397 with upregulated expression in erALK-TKI cells belonged to distinct gene co-expression 398 clusters, suggesting that the resistance-associated changes in gene expression are unlikely to 399 represent a single coordinated transcriptional program switch (Fig. S8A, B) . Notably, gene set 400 enrichment analysis revealed several shared enriched gene sets (Fig. S8C) . In particular, all of 401 the examined resistant cell lines displayed an epithelial to mesenchymal transition (EMT) 402 signature. Whereas EMT has been described as ALK-TKI resistance mechanism 34,35 , our results 403 suggest a need for a more nuanced interpretation, given the differences in specific resistance 404 associated molecular changes observed in different erALK-TKI cell lines, which would be 405 missed under the EMT umbrella term. 406 407
To gain further insights into the dynamics of phenotypic changes during the evolution of 408 resistance, we analyzed phenotypic changes following different exposure times to ALK TKIs 409 using single cell expression profiling. Notably, UMAP analysis revealed gradual phenotypic 410 progression from naïve to resistant phenotypes ( Fig. 5B, S9 ). Even brief (4 hours) alectinib 411 exposure substantially impacted cell phenotypes, suggesting that acquisition of resistance might 412 reflect not only the action of drug-imposed selection, but also direct drug-induced cell 413 adaptation. On the other hand, some of the naïve cells mapped to a major phenotypic cluster of 414 one of the erCriz (erCriz3) samples ( To explore a possible epigenetic mechanism underlying the observed early and heritable 426 changes in gene expression associated with ALK-TKI exposure, we analyzed the global 427 repatterning of Histone 3.3 lysine 27 acetylation (H3K27ac), a post-translational histone 428 modification associated with strong enhancer elements. We performed ChIP-Seq analysis to 429 characterize differential H3K27ac distribution at gene regulatory elements in naïve and evolved 430 resistant lines. We found that different ALK-TKI resistant phenotypes are associated with 431 distinct global patterns of H3K27 acetylation (Fig. S10A) . Changes in gene expression in the 432 resistant cell lines were associated with changes in H3K27 acetylation (Fig. S10B) . 433 Consistently, we found new H3K27ac peaks in the vicinity of genes upregulated in individual 434 ALK-TKI treated lines, e.g. ERBB2 / HER2 (Fig. S10C) . Consistent with the differences in 435 protein expression (Fig. 1F ) the new peaks were observed in erAlec and erLor lines, but not in 436 the erCriz lines. Interestingly, new peaks were also observed for genes with chromosomal 437 genomic amplification in relevant cell lines (EML4, K-RAS and N-RAS) (Fig. 12D) , suggesting 438 the involvement of both genetic and epigenetic mechanisms in the elevated expression of 439 putative drivers of resistance. Taken together, these data suggest that stable gene expression 440 changes, in resistance-associated genes, might be established and maintained by a 441 combination of genetic and epigenetic changes. 442 443
To evaluate the functional significance of elevated expression of the resistance-associated 444 genes on ALK-TKI sensitivity, we tested the impact of overexpression of selected genes, 445 previously implicated in TKI resistance. We found that lentiviral overexpression of HER2, FGFR, 446 AXL, and SLUG significantly increased resistance to multiple ALK-TKIs (Fig. 5D) . However, 447 similar to the insufficiency of EML-4 ALK amplification to fully account for ALK-TKI resistance, 448 resistance levels observed in these engineered cell lines fell short of levels observed in the 449 erALK-TKI lines, suggesting that evolved resistance might reflect the combined effect of multiple 450 contributing changes. To directly evaluate this possibility, we interrogated the impact of the 451 combination of individual genetic and transcriptional changes. We combined overexpression of 452 EML4-ALK, which is amplified in many resistant cell lines (Fig. 1F) and provides a very modest 453 decrease in crizotinib sensitivity (Fig. 4F) , with expression of HER2 (at lower levels compared to 454 overexpressing cells used for Fig. 5B ), which is also elevated in multiple erALK-TKI cell lines 455 ( Fig. 1F ) and can provide modest resistance to different ALK inhibitors, when overexpressed at 456 high levels (Fig. 5D ). Whereas HER2 overexpression had very limited impact on ALK-TKI 457 sensitivity, it significantly increased resistance conferred by EML4-ALK overexpression, though 458 still failing to recapitulate resistance levels observed in erALK-TKI cells (Fig. 5E) taken off the drugs indeed proliferated slower than drug naïve control, some of the resistant cell 472 lines proliferated at similar or even higher rates (Fig. S11A) . Interestingly, all of the examined 473 erCriz and 1 out of 3 of the examined erAlec cell lines displayed higher rates of proliferation in 474 the presence of the inhibitors, consistent with previously reported observations in 475 melanoma 40, 41 . The remaining cell lines were either modestly inhibited, or unaffected by the 476 ALK-TKI used for their selection (Fig. S11A) alectinib in the presence of dual EGFR/HER2 inhibitor lapatinib (Fig. S12A) . However, erAlec 497 cells were not sensitized to lapatinib as a single agent, and only some of the independently 498 derived erAlec cell lines were inhibited by the combination of alectinib and lapatinib (Fig. S12B) . 499 To examine this apparent discrepancy, we examined the sensitivity of intermediate stages of 500 alectinib resistance to lapatinib. We found that evolving cells were remarkably sensitive to 501 lapatinib, even as a single agent, although this sensitivity gradually diminished as cells became 502 more resistant to alectinib (Fig. 6A, B) . Notably, this sensitivity cannot be explained by pre-503 existence of lapatinib sensitive, alectinib tolerant sub-populations, as treatment with 10 µM 504 lapatinib for up to 3 weeks did not substantially impact sensitivity of H3122 to alectinib (Fig.  505  S12C) . Consistently, administration of lapatinib as a single agent, following an initial three 506 weeks in alectinib, or as a combination therapy, was able to achieve complete elimination of 507 H3122 cells in vitro (Fig 6C) . 508 509
Encouraged by this observation, we asked whether alectinib/lapatinib cycling or a combination 510 treatment with the two drugs could outperform alectinib monotherapy in vivo. We found that 511 lapatinib was completely ineffective in adaptive cycling with alectinib, as tumor relapse during 512 lapatinib cycles was indistinguishable from the relapse observed with a drug holiday (Fig. 6D) . 513 Most likely, this lack of efficiency in vivo reflects its inability to reach the high concentrations 514 required to achieve collateral sensitivity in vitro. Still, lapatinib significantly increased tumor 515 sensitivity to alectinib in a combination therapy setting (Fig. 6D) The second framework views resistance as the result of drug-induced reprogramming, where 554 phenotypic plasticity enables tumor cells to directionally "rewire" their signaling, metabolic and 555 gene-expression networks to cope with inhibitor-induced perturbations 13, 55, 56 . In this system-556 biology based framework, resistance can be gradual and multifactorial, however the causal role 557 of selection is sometimes rejected due to its link with the mutation-centric paradigm 13 . 558 559
The two frameworks are not necessarily viewed as strictly mutually exclusive, as they can be 560 bridged in a two-step process involving reprogramming mediated formation of DTP sub-561 populations followed by an (epi) mutational switch to full resistance. Our results, however, 562
suggest an alternative scenario of gradual, multifactorial resistance, which integrates features of 563 the two paradigms described above. Based on i) the observation of gradual development of 564 resistance from heterogeneous weakly resistant sub-populations, ii) the co-occurrence of both 565 genetic and non-genetic changes, of which at least some appear to be directly induced by drug 566 exposure, iii) the insufficiency of single resistance-associated mechanisms to confer full 567 resistance, and iv) the additive action of individual resistance-associated mechanisms, we 568 propose the following model: Selective pressures imposed by therapies act on phenotypic 569 heterogeneity, stemming from both stochastic (genetic and epigenetic) and drug-induced 570 changes, leading to a gradual increase in population fitness through acquisition of additional 571 genetic and epigenetic changes until a local fitness peak is reached (Fig. 6F) The proposed concept of gradual resistance does not exclude the possibility of pre-existence of 591 full resistance, or a mixed scenario, where tumor relapse might reflect a combined contribution 592 of both pre-existing and gradually evolving de novo resistance. Indeed, our single cell profiling 593 experiments revealed pre-existence of phenotypes that mapped to a major phenotypic cluster in 594 one of the erCriz cell lines (Fig. 1G) . Our framework is also compatible with the possibility that 595 some mutational events lead to a dramatic fitness increase, which represents a special case 596 within a more inclusive paradigm. On the other hand, given the evidence of the insufficiency of 597 well-recognized "causes" of resistance such as EML-ALK amplification, single copy L1196M 598 mutation, and alternative RTK overexpression to confer maximal resistance in the H3122 599 experimental model (Fig. 4F) , it is also possible that at least in some cases, attribution of 600 resistance to a single mechanism might be incorrect. We would like to point out that a 601 commonly used research study algorithm, which investigates how drug sensitivity is modulated 602 by up and down regulation of a putative resistance "driver", followed ; where is 638 luminescence, is drug concentration, 50 is the half maximal inhibitory concentration, is the 639 hill slope and is the luminescence as the drug concentration approaches ∞. 640 Clonogenic Assays. Cells were plated in the presence of ALK-TKIs or DMSO vehicle control at 641 varying densities into 6 cm dishes or multi-well plates in duplicates or triplicates, and grown for 642 10 days, at which points they were fixed and stained with crystal violet, following protocols 643 described in 59 . To measure the evolution of gradually increasing resistance, nuclear mCherry 644 expressing H3122 cells were plated at ~400,000 cells per 6cm dish, allowed to attach overnight, 645 and exposed to DMSO vehicle control, 0.5μM crizotinib or 0.5μM lorlatinib the following day. 646
After culturing for 1-3 weeks, cells were harvested and seeded in 96-well plates (Costar) at 50 647 cells/well for DMSO control, or between 50 and 500 cells for crizotinib and lorlatinib. Number of 648 colonies and colony sizes were measured 1 week later for colonies larger than 1000 pixels (~5 649 cells), based on fluorescent area. To minimize the impact of variability in seeding numbers, 650 clonogenic survival in the presence of ALK inhibitors was normalized to clonogenic data in the 651 DMSO controls. 652
Determining frequency of Resistance Initiating Cells. Cells were plated with initial seeding 653 densities of 400, 400, 800, 1400 and 400 cells/well in DMSO (0.1%), crizotinib (0.5µM), ceritinib 654 (0.1µM), alectinib (0.5µM) and lorlatinib (0.5µM) treated plates respectively, in a 96-well plate 655 (Falcon). Five additional 2x dilutions were generated from these wells, each with 10 separate 656 wells. ALK inhibitors were added after 24h. After 7 weeks of treatment, wells containing no 657 colonies larger than ~ 50 cells were counted. The natural log of the proportion of wells without 658 colonies was fitted linearly against the initial cell number in each well. Heatmap.2 in R (using default parameters) was used for heatmap clustering. Corrplot 60 in R 674 (using spearman correlation coefficients) was used to visualize correlations. 675
Fluorescent In Situ Hybridization Analyses. Cells were cultured in 10 cm dishes in 10 ml of 676 1640 medium supplement with 10% FBS. After 24 hours, 100 µl of colcemid (10 µg/ml, Life 677
Technologies, Carlsbad, CA) was added to each culture, and culture replaced to incubator for 678 another one hour before harvesting. Cell suspension was transferred to 15 ml cortical 679 tubes. Culture medium was removed by centrifuge at 1000 rpm for 5 min. Cell pellets were 680 subjected to hypotonic treatment with 0.075M KCl and then fixed with Methanol and acidic acid 681 at 3:1v/v. Cell suspensions were dropped to slides, and treated with 0.005% (wt/vol) pepsin 682 solution for 10 min, followed by dehydration with 70%, 85%, and 100% (vol/vol) ethanol for 2 683 min each. Hybridization was performed by adding 10 µl of ALK dual color break apart probe on 684 each slide (Cytocell, Cambridge UK), a coverslip was placed, and the slides were sealed with 685 rubber cement. The specimens were subjected to denaturation at 75 °C for 3 min and 686 hybridized at 37 °C for 16 h. The slides were washed in 0.4× saline-sodium citrate at pH 7.2 and 687 then counterstained with DAPI. Results were analyzed on a Leica DM 5500B fluorescent 688 microscope. Cell images were captured in both interphase and metaphase cells. 689 RNAseq Analysis. Following 48 hours of culturing in the absence of inhibitors (to minimize the 690 impact of directly induced gene expression changes), RNA was isolated for erALK-TKI and 691 parental H3122 cells using an RNAEasy Minikit (Qiagen). Reads were generated using a MiSeq 692 instrument. Alignment was achieved using HiSat2 and the human hg19 reference genome. 693
Normalized reads were obtained from DeSeq2. Analysis was performed with genes with more 694 than 25 reads in at least one sample and more than two-fold change from ALK TKI naïve cells in 695 at least one resistant line. 696 Nanostring Assay. Following 48 hours of culturing in the absence of inhibitors (to minimize the 697 impact of directly induced gene expression changes), RNA was isolated for erALK-TKI and 698 parental H3122 cells using an RNAEasy Minikit (Qiagen).The nCounter GX Human Cancer 699
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